To test if innate immunity could modulate the therapeutic effect of the drug combination, we simultaneously treated nude mice and NOD-SCID-γ (NSG) bearing HCT116 CRC tumors, which harbor a PIK3CA mutation, with vehicle control, CB839, 5-FU, or the drug combination (Comb). This evidence concerns the gene PIK3CA and colorectal carcinoma.